The Deepbridge Life Sciences EIS team prepares and reviews investment opportunities sourced from a wide dealflow network. Generally, Deepbridge seeks investment opportunities that exhibit the following qualities:
- A focus on life sciences and medical device technology;
- Significant market potential with clear need and market growth;
- Provide a solution to a recognised clinical or healthcare need;
- Innovation-driven products that have the potential to create new market segments or displace current technologies;
- Medical technology businesses with a clear and realistic path to commercialisation;
- Robust intellectual property which may provide patented or patentable IP protection
- Passionate, energetic, experienced and aligned founding team;
- Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders.
Deepbridge will take an active executive role on the Board of the investee companies to utilise the strengths and commercial experience that the Deepbridge team possess in order to accelerate the growth of the investee company.
For more information on the Deepbridge Life Sciences EIS, please click here.
Dr Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital.
- November 2022 (3)
- October 2022 (3)
- September 2022 (8)
- August 2022 (6)
- July 2022 (2)
- June 2022 (1)
- May 2022 (8)
- April 2022 (7)
- March 2022 (7)
- February 2022 (9)
- January 2022 (13)
- December 2021 (3)
- November 2021 (5)
- October 2021 (7)
- September 2021 (4)
- August 2021 (4)
- July 2021 (3)
- June 2021 (6)